** Brokerage Scotiabank upgrades life sciences tool maker Waters Corp WAT.N rating to "sector outperform" from "sector perform", raises PT to $450 from $430
** Brokerage says the rating is based on WAT's strong Q4 financial performance and 2025 profit forecast
** The price target is justified due to the timing of its clients' instrument replacement cycles, significant revenue from life science applications, and a leading position in emerging markets such as GLP-1 obesity drugs and generic drugs in India - Scotiabank
** "On the bottom line, WAT continues to have significant EPS leverage, driven by its industry leading margins, recently initiated productivity and pricing initiatives and cash deployment capacity" - brokerage
** Stock rose 21.7% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。